🇺🇸 FDA

Company profile · Sponsor

Pharming

Pharming Technologies B.V.

E20F51D · EMA pharma EU
Pipeline
8
Drugs
0
Patents
0

Quick answer

Pharming (E20F51D) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E20F51D
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (8)

Search pipeline →

  1. CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 3 small molecule active

    1 trial

  2. CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 3 small molecule active

    1 trial

  3. An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

    Pharming

    Adult patients with primary mitochondrial disease

    phase 2 other active

    1 trial

  4. CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming

    Common variable immunodeficiency

    phase 2 small molecule active

    1 trial

  5. CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming

    primary immunodeficiency

    phase 2 small molecule active

    1 trial

  6. An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharmacokinetics (PK) of caffeine, midazolam, rosuvastatin, furosemide, and metformin in healthy subjects

    Pharming

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 1 other active

    1 trial

  7. An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic function

    Pharming

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 1 other active

    1 trial

  8. CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is Pharming?

Pharming (E20F51D) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Pharming sponsor?

We track 8 ClinicalTrials.gov-linked programs for Pharming, including CDZ173/Leniolisib, CDZ173/Leniolisib and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Pharming company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.